Dr. Hugo Hool, MD
Hematology & Oncology (Hematology & Oncology Physician)
3285 Skypark Dr
Torrance, CA 90505
Who else practices at this address →
Los Angeles County includes primary care (7% of residents) and mental health (13% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- Rutgers R W Johnson Medical School (Cam/New Bruns/Pisc) (1997)
- Years since graduation
- 29
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 335
Licensed in California since 1998, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1997Medical school: Rutgers R W Johnson Medical School (Cam/New Bruns/Pisc)
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
CA license A66860 (first issued 1998; current)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Torrance Memorial Medical Center Torrance, CA
- Providence Little Company of Mary Med Ctr Torrance Torrance, CA
Medical groups
- Torrance Health Association Inc (299 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 335
- Services billed
- 161,570
- Patients’ average age
- 78
| Service | Times | Patients |
|---|---|---|
| Injection, fosaprepitant, 1 mg | 16,950 | 17 |
| Injection, heparin sodium, (heparin lock flush), per 10 units | 13,755 | 26 |
| Injection, dexamethasone sodium phosphate, 1 mg | 2,268 | 27 |
| Injection, granisetron hydrochloride, 100 mcg | 2,111 | 25 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 1,232 | 236 |
| Established patient office or other outpatient visit, 30-39 minutes | 730 | 231 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 469 | 26 |
| Established patient office or other outpatient visit, 40-54 minutes | 388 | 89 |
| Administration of chemotherapy into vein, 1 hour or less | 295 | 39 |
| Established patient office or other outpatient visit, 20-29 minutes | 272 | 170 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prednisone Other prescribers in Torrance, CA | 98 |
| Letrozole Other prescribers in Torrance, CA | 89 |
| Eliquis (apixaban) Other prescribers in Torrance, CA | 78 |
| Abiraterone Acetate | 40 |
| Jakafi (ruxolitinib phosphate) | 30 |
| Valacyclovir (valacyclovir hcl) Other prescribers in Torrance, CA | 26 |
| Nubeqa (darolutamide) | 24 |
| Xarelto (rivaroxaban) Other prescribers in Torrance, CA | 23 |
| Pomalyst (pomalidomide) | 23 |
| Hydroxyurea Other prescribers in Torrance, CA | 22 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 8 companies reported 17 payments worth $365 in total to this clinician.
| AstraZeneca Pharmaceuticals LP | $149 |
|---|---|
| Puma Biotechnology, Inc. | $65.38 |
| Celgene Corporation | $32.34 |
| Array Biopharma Inc | $27.23 |
| Merck Sharp & Dohme LLC | $27.06 |
| Genentech USA, Inc. | $25.76 |
| E.r. Squibb & Sons, L.l.c. | $20.41 |
| Janssen Biotech, Inc. | $17.06 |
| Food and Beverage | $365 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 6 industry-funded studies in 2025, from 5 companies. The companies reported $96,482 in research payments for these studies, mostly to the institutions running them.
- A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastat…
Janssen Research & Development, LLC - A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With KRAS/NRAS and BRAF Wildtype Recurrent Metastatic Colorectal Cancer Who Have Received Prior Ch…
Janssen Research & Development, LLC - An Open-label, Randomised, Multicentre, Phase III Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Leucovorin Versus Nab-paclitaxel Plus Gemcitabine in Subjects Who Have Not Previously Received Chem…
Ipsen Bioscience Inc. · NCT04083256 - A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects with Metastatic Colorectal Cancer
Exelixis Inc. - A Phase 1b/3 Study of Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab Alone in Subjects With Previously Untreated Advanced Gastric and Gastroesophageal Junction Cancer With FGFR2b Overe…
Amgen Inc. - A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)
Eli Lilly and Company · Active, not recruiting · NCT05288166
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.